Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Eric Haltom"'
2
Phase I trial of PT-100 (PT-100), a cytokine-inducing small molecule, following chemotherapy for solid tumor malignancy
Autor: Eric Haltom, Neil Senzer, Donald Richards, Houston Duncan, John Nugent, Svetislava J. Vukelja, Barry Jones, Margaret J. Uprichard, Casey Cunningham, John Nemunaitis
Publikováno v: Cancer investigation. 24(6)
PT-100 upregulates cytokine expression competitively inhibiting the dipeptidyl peptidase activity of fibroblast activation protein (FAP) and dipeptidyl peptidase IV (DPP-IV). This dose-escalation study was conducted to evaluate the safety of PT-100 i
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6432d238e2a3ceba5c91454e2ec8ddb1
https://pubmed.ncbi.nlm.nih.gov/16982458
Zobrazit plný text záznamu
3
Abstract 3276: A Phase 1 dose escalating study with ACE-041, a novel inhibitor of ALK1 mediated angiogenesis, in patients with advanced solid tumors
Autor: Sunil Sharma, Yijun Yang, Matthew L. Sherman, Johanna C. Bendell, Michael S. Gordon, Herbert Hurwitz, Kenneth M. Attie, Dawn Wilson, Eric Haltom, Carolyn H. Condon
Publikováno v: Cancer Research. 71:3276-3276
Background: Activin receptor-like kinase-1 (ALK1) is a type I receptor predominantly expressed on activated vascular endothelial cells that mediates signaling by members of the TGFß superfamily of proteins. ACE-041, a soluble receptor fusion protein
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ddb7b3e0b797c574f8a451983ee4bd18
https://doi.org/10.1158/1538-7445.am2011-3276
Zobrazit plný text záznamu
4
ACE-011, a Soluble Activin Receptor Type Iia IgG-Fc Fusion Protein, Increases Hemoglobin (Hb) and Improves Bone Lesions in Multiple Myeloma Patients Receiving Myelosuppressive Chemotherapy: Preliminary Analysis
Autor: Matthew L. Sherman, Kudrat Abdulkadyrov, Gary Renshaw, Galina Salogub, Robert Knight, Eric Haltom, Yijun Yang, Niels Borgstein, Nuriet K. Khuazheva, Rachel Woolf
Publikováno v: Blood. 114:749-749
Abstract 749 Background: Anemia is frequently observed in multiple myeloma (MM) patients and can result from cumulative marrow suppression by chemotherapy, invasion of bone marrow by tumor cells, renal insufficiency and other causes. The vast majorit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbc7ed7e17d8682fa83861bbda5bbaf9
https://doi.org/10.1182/blood.v114.22.749.749
Zobrazit plný text záznamu
5
ACE-011, a soluble activin receptor type IIA IgG-Fc fusion protein, decreases follicle stimulating hormone and increases bone-specific alkaline phosphatase, a marker of bone formation, in postmenopausal healthy women
Autor: Yijun Yang, Morris Sherman, N.G. Borgstein, Eric Haltom, Carolyn H. Condon
Publikováno v: Cancer Research. 69:1160
Abstract #1160 Breast cancer metastasizes to bone in up to 85% of patients with advanced disease. Skeletal-related morbidity such as pathologic fractures, spinal cord compression, or the need for radiotherapy or surgery to the bone will occur in the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::17381cddb977437e21d874088dba8f87
https://doi.org/10.1158/0008-5472.sabcs-1160
Zobrazit plný text záznamu
6
ACE-011, a Soluble Activin Receptor Type IIa IgG-Fc Fusion Protein, Increases Hemoglobin and Hematocrit Levels in Postmenopausal Healthy Women
Autor: Niels Borgstein, Michelle D Ababa, Yijun Yang, Sandeep K. Reddy, Louisa Mook, Eric Haltom, Kenneth Kim, Matthew L. Sherman
Publikováno v: Blood. 112:3866-3866
ACE-011 is a soluble fusion protein consisting of the extracellular domain of activin receptor IIA linked to the Fc portion of human IgG1 and is a potent activin antagonist. ACE-011 is currently in clinical development for the treatment of bone loss
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5126c3271cabb9e34a953c80e7992ae3
https://doi.org/10.1182/blood.v112.11.3866.3866
Zobrazit plný text záznamu
7
Phase 2 Study of Talabostat and Rituximab in Patients with Advanced Chronic Lymphoctyic Leukemia (CLL) Previously Treated with a Rituximab/Fludarabine Regimen
Autor: Margaret J. Uprichard, Anne Marie Maddox, Susan O'Brien, Jennifer R. Brown, P. Cook, Alison M. Duarte, Khuda Dad Khan, Eric Haltom, Kanti R. Rai
Publikováno v: Blood. 106:2125-2125
Background: Talabostat (T) is an orally available inhibitor of dipeptidyl peptidases (DPP) such as fibroblast activation protein (FAP). FAP is expressed in bone marrow, lymph nodes, and the stroma of solid tumors. T induces the production of cytokine
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc898b0858fa25e426b521d00cbf6e52
https://doi.org/10.1182/blood.v106.11.2125.2125
Zobrazit plný text záznamu
9
Phase 1 Study of Talabostat and Rituximab in Patients with Indolent Non-Hodgkin’s Lymphoma with Primary Resistance to or Progression Following Rituximab
Autor: Joe Stephenson, David D. Hurd, Francis J. Giles, Robert N. Raju, Ayad Al-Katib, Margaret J. Uprichard, Eric Haltom
Publikováno v: Blood. 104:1403-1403
Background: Talabostat (PT-100), an orally available inhibitor of dipeptidyl peptidases, is in Phase 2 studies for B-cell malignancies and solid tumors. Talabostat increases production of cytokines and chemokines in lymph nodes and spleen, stimulatin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::abc1be31c0b273b92a79cf144ad5e96e
https://doi.org/10.1182/blood.v104.11.1403.1403
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje